Lupin collaborates with AbbVie for $977m MALT1 inhibitor program targeting hematological cancers
Indian pharmaceutical company Lupin has entered a landmark agreement to out-license its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program to US-based biopharmaceutical ... Read More
Martindale Pharma’s Epaclob and Silocalm gain regulatory approval in seven European countries
Martindale Pharma, a UK-based global pharmaceutical company, has successfully secured regulatory approval for its innovative clobazam oral suspension, branded as Epaclob and Silocalm, in seven ... Read More